TrialsgramBetaRCTs are beautiful
TCT 2026Präsentiert So., 1. Nov. · 14:51 GMT-8Late-Breaking Clinical Science: Session I, in Collaboration with CirculationAlle Studien (Late-Breaking) →

TRAVEL III

2026

Transcatheter Tricuspid Valve Replacement with the LuX-Valve Plus System vs. Medical Therapy for Severe TR (TRAVEL III)

In patients with severe tricuspid regurgitation, transcatheter tricuspid valve replacement with the LuX-Valve Plus system plus optimal medical therapy improved the 6-month composite endpoint compared with medical therapy alone.

Ergebnis

Primärer Endpunkt: Composite endpoint at 6 months; major adverse events at 30 days (per the probable registration)

The composite endpoint event rate difference was 78.1% (P<0.001), with TTVR plus optimal medical therapy significantly better than medical therapy alone. Procedural success was 98.7%.

Originalpublikation
Unterthema
Transcatheter tricuspid replacement
Design
Prospective, multicentre randomised trial in China; transcatheter tricuspid valve replacement with the LuX-Valve Plus system plus optimal medical therapy versus optimal medical therapy alone, in patients aged 65 or older with severe or greater TR, NYHA III-IV, at high surgical risk
Eingeschlossen
118 Patienten
Quelle
Ge J, et al. Presented at TCT 2026, 1 November. Jenscare Scientific voluntary announcement (09877.HK), 2 November 2026. Not yet published.

Diskussion & Kritik

The trial is randomised and multicentre, and the sponsor reports a large difference in the composite endpoint in favour of valve replacement at 6 months. The announcement gives no arm values, no confidence interval, no components of the composite and no safety figures, so the size and drivers of the effect cannot be judged. Follow-up is only 6 months in 118 patients, the comparator is medical therapy alone, and the announcement does not say whether the trial was blinded. The only source is the sponsor's own announcement, and the trial is not yet published.